Natera, Inc. (NTRA) News
Filter NTRA News Items
NTRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NTRA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock HoldingsAs revealed in Duquesne's latest 13F regulatory filing, its top five stocks as of mid-November 2024 were Natera (NASDAQ: NTRA), Coupang (NYSE: CPNG), Coherent (NYSE: COHR), Woodward (NASDAQ: WWD), and Seagate Technology (NASDAQ: STX). All booked at least double-digit gains across 2024. |
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceAUSTIN, Texas, January 07, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, Jan. 15, 2025 at 9:00 a.m. PT (12:00 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at the conference. |
Six IBD 50 Stocks Bear Gifts Even As Santa Claus Rally FizzlesThe stock market rally fizzled as 2024 wrapped up. That has led a new set of buying opportunities among leaders that pulled back to key levels. |
High Growth Tech Stocks To Watch In January 2025Over the last 7 days, the United States market has dropped 2.8%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% annually in the coming years. In this context of fluctuating short-term performance and promising long-term growth prospects, identifying high-growth tech stocks involves looking for companies with strong innovation potential and solid financial fundamentals that can withstand market volatility. |
3 US Stocks That May Be Trading At A DiscountAs the United States stock market begins 2025 on a cautious note, extending a recent slump with major indices like the S&P 500 and Nasdaq Composite experiencing consecutive losing sessions, investors are keenly observing potential opportunities amidst the downturn. In this environment, identifying undervalued stocks becomes crucial as these may offer attractive entry points for those looking to capitalize on discrepancies between current market prices and intrinsic value. |
Natera's (NASDAQ:NTRA) investors will be pleased with their enviable 353% return over the last five yearsBuying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly... |
Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average? |
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomicsAUSTIN, Texas, December 17, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests. |
What Makes Natera (NTRA) a Top Stock Pick for Billionaire Stanley Druckenmiller?We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stock Picks. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against other Billionaire Stanley Druckenmiller’s stock picks. Druckenmiller on the Fed’s Actions On November 6, billionaire Stanley Druckenmiller appeared in a podcast, In Good Company, hosted […] |
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon CancerAUSTIN, Texas, December 12, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinical trial designed to evaluate the use of Signatera to guide personalized adjuvant treatment strategies for patients wi |